ERBB2 and breast carcinoma: The advances in breast cancer management, as for example the shift to administrating anthracyclines and anti-HER2 agents in sequence and not concomitantly, as well as the increasing popularity of de-escalation efforts with anthracycline-free regimens in patients, will lower the risk for toxicity, and advances in radiotherapy techniques are expected to further decrease cardiotoxicity incidence.